Search
GI Cancer
EAY191-S3
Molecular Analysis for Combination Therapy Choice (ComboMATCH): Protocol EAY191-S3, Phase II Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors
NRG GI011 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
A Phase III Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC)
NSABP FC-13 **ARMS 1 and 2 Only**
A Phase II Platform Study to Evaluate Treatment with Cemiplimab Monotherapy or Cemiplimab plus Fianlimab or Other Novel Combinations in Patients with Colorectal Cancer with Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
S2418CD
A Pragmatic Randomized Controlled Trial To Evaluate The Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance
S2408 (MBMC Only)
A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula
NRG CC014 (XRT at MBMC Only)
Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT)
EAQ222CD
Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients
A022102 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
RANDOMIZED PHASE III TRIAL OF MFOLFIRINOX +/- NIVOLUMAB VS. FOLFOX +/- NIVOLUMAB FOR FIRST-LINE TREATMENT OF METASTATIC HER2-NEGATIVE GASTROESOPHAGEAL ADENOCARCINOMA
A022101 (Radiation Therapy at MBMC Only)
A PRAGMATIC RANDOMIZED PHASE III TRIAL EVALUATING TOTAL ABLATIVE THERAPY FOR PATIENTS WITH LIMITED METASTATIC COLORECTAL CANCER: EVALUATING RADIATION, ABLATION, AND SURGERY [ERASUR]
EAY191-N5 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
A Randomized Trial of Neratinib, a Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors. A ComboMATCH Treatment Trial
